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Abstract. Glucocorticoids (GCs) are a class of steroid 
hormones which regulate a variety of essential biologi-
cal functions. The profound anti-inflammatory and im-
munosuppressive  activity  of  synthetic  GCs,  combined 
with their power to induce lymphocyte apoptosis place 
them  among  the  most  commonly  prescribed  drugs 
worldwide. Endogenous GCs also exert a wide range of 
immunomodulatory activities, including the control of 
T cell homeostasis. Most, if not all of these effects are 
mediated through the glucocorticoid receptor, a member 
of the nuclear receptor superfamily. However, the signal-
ing pathways and their cell type specificity remain poorly 
defined. In this review, we summarize our present knowl-
edge on GC action, the mechanisms employed to induce 
apoptosis and the currently discussed models of how they 
may participate in thymocyte development. Although our 
knowledge in this field has substantially increased during 
recent years, we are still far from a comprehensive pic-
ture of the role that GCs play in T lymphocytes.
* Corresponding author.
Key words. Apoptosis; glucocorticoid; T cell development; caspase; Bcl-2 family; transgenesis; gene targeting.
Introduction
T cells form a major branch of the acquired immune 
system  [1]. They  derive  their  name  from  the  thymus, 
where they develop to immunocompetent T lymphocytes 
through a series of lineage and selection steps. This en-
sures that all cells which lack a functional T cell receptor 
(TCR) or bear a TCR with useless or dangerous specifi-
city are deleted [2]. In the periphery, mature T cells un-
dergo clonal expansion upon encountering their cognate 
antigen. Once the invading pathogen is cleared, the su-
perfluous lymphocytes are removed in a process known 
as activation-induced cell death (AICD) [3]. Thus, both 
during thymocyte development and T cell-mediated im-
mune responses, it is essential that cells are deleted in a 
controlled manner to prevent immunopathologies such as 
autoimmunity and cancer. This is achieved by a process 
called apoptosis [4] which, among other things, involves 
a series of proteolytic events that result in characteristic 
morphological  alterations  and  ultimately  lead  to  cell 
death.
Glucocorticoids (GCs) are a class of steroid hormones 
which display potent immunomodulatory activities in-
cluding the ability to induce T lymphocyte apoptosis 
[5]. Although this was one of the first recognized forms 
of programmed cell death, it is still poorly understood 
[6]. GCs exert most, if not all, of their effects through 
binding to the glucocorticoid receptor (GR), a ligand-
activated transcription factor [7]. While GR-mediated 
gene  activation  is  clearly  an  essential  component  of 
the apoptotic pathway [8], the downstream events are 
debatable. Although GC-induced cell death does not 
directly proceed via one of the two classical apoptotic 
pathways, Bcl-2 proteins and caspases still appear to Cell. Mol. Life Sci. 63 (2006) 60–72
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be involved in this process [5, 9, 10]. Furthermore, the 
physiological role of GC-induced T cell apoptosis is 
also not fully resolved. GCs have been hypothesized 
to direct positive and negative selection in the thymus 
[11], to limit AICD during the contraction phase of an 
adaptive immune response [12] and to induce general-
ized thymocyte apoptosis after polyclonal T cell acti-
vation [13]. This has been assigned to effects of both 
adrenally derived hormones as well as GCs synthesized 
within the thymus itself. Thus, not only the mechanism 
but also the physiological function of GC-induced ap-
optosis requires further investigation. Owing to their 
ability  to  mediate  apoptosis  in  leukemia,  lymphoma 
and myeloid cells, synthetic GCs are among the most 
widely prescribed drugs for the treatment of hemato-
logical  maligancies  [10,  14].  Consequently,  a  better 
understanding of GC-induced apoptosis is not only of 
theoretical interest but is also urgently required to im-
prove the suitability of these drugs for clinical therapy. 
In this review we try to provide a broad picture of how 
GCs contribute to the development and apoptosis of 
thymocytes and mature T cells and the molecular mech-
anisms, signaling pathways and enzymatic systems that 
may be utilized during their action. Furthermore, we 
summarize how the generation and analysis of trans-
genic, knock-out and knock-in mice has contributed to 
our present knowledge about these processes [15]. We 
hope this provides the basis for a better understanding 
of this important class of steroid hormones and their 
role in T cell immunology. 
The molecular and physiological basis of GC action
The glucocorticoid receptor
The  GR  belongs  to  the  nuclear  receptor  superfamily 
which are characterized by their common arrangement of 
functionally distinct domains mediating transactivation, 
DNA binding, nuclear localization, dimerization and lig-
and recognition [16]. In the absence of hormone, the GR 
is found within a multimeric complex of heat shock pro-
teins and immunophilins in the cytoplasm [17] (fig. 1). 
GCs such as cortisol in humans and corticosterone in 
rodents diffuse passively into the cell, where they bind to 
the GR [7]. Following dissociation from the heat shock 
protein complex, the GR translocates into the nucleus. 
There it recognizes imperfect palindromic sequences, so-
called glucocorticoid response elements (GREs), present 
in  the  promoter  and  enhancer  regions  of  a  variety  of 
genes [18]. The GR can drive transcription from these re-
sponse elements by using its surfaces as platforms for the 
docking of transcriptional coactivators that are capable of 
altering the local chromatin or recruiting and stabilizing 
the transcription machinery [19].
Although many genes are known to be upregulated in 
response to GCs, including some important to the acti-
vation, function and apoptosis of immune cells, such as 
Bcl-xL [20], IkB [21], GILZ [22] and GITR [23], there is 
scant evidence that they are directly upregulated through 
GREs. Genes which have been shown to be positively 
regulated through well-defined GREs in vivo include ty-
rosine amino transferase [24] and phosphoenolpyruvate 
carboxykinase [25]. In contrast to these DNA binding-
Figure  1.  Molecular  modes 
of GR action. GCs passively 
diffuse into the cell and bind 
to the GR (1). This results in 
the  dissociation  of  the  heat 
shock protein complex (Hsps) 
(2)  and  translocation  of  the 
ligand-bound GR into the nu-
cleus. There the GR modulates 
transcription either by binding 
to DNA (3) or via interaction 
with  other  transcription  fac-
tors (4). Non-genomic mecha-
nisms  of  GR  action  include 
interference  with  cytosolic 
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dependent activities, the GR also regulates gene expres-
sion by interfering with other transcription factors such 
as NF-kB [26], AP-1 [27], NF-AT [28], CREB [29] and 
Stat5 [30]. Intriguingly, the GR can control gene expres-
sion  in  this  way,  mostly  in  a  transrepressing  manner, 
without binding to DNA itself (fig. 1). This was most 
convincingly demonstrated by introducing a point muta-
tion into the GR which prevents it from both dimerizing 
and binding DNA [8]. When present in the germline of 
knock-in mice (GRdim), the mutated GR was unable to 
mediate transcription from GREs but its ability to regu-
late transcription from AP-1-, NF-kB- and Stat5-driven 
promoters was not compromised [31–34]. In addition to 
its established effects on transcription, evidence is grow-
ing that the GR can also play a role in cytosolic signaling 
pathways, including the activation of PI3 kinase [35]. 
It  has  also  been  recently  recognized  that  multiple  N-
terminal  isoforms  are  generated  from  the  GR  gene 
by  translational  mechanisms  [36].  Importantly,  these 
isoforms appear to regulate different sets of genes, sug-
gesting that they are not functionally equivalent. Given 
the tissue-specific distribution of the various isoforms, it 
will be intriguing to see whether they are differentially 
involved in immunoregulatory functions in the same way 
that the use of alternative promoters of the GR has been 
shown to correlate with the sensitivity of T lymphocytes 
to apoptosis [37, 38]. Taken together, differential tran-
scription and translation events give rise to a plethora of 
GR species which control cellular processes by several 
different mechanisms [39]. This in turn forms the basis 
for the variety of activities that GCs exert in the immune 
system.
Control of GC secretion and synthesis
The primary site of GC synthesis is the adrenal gland, 
which was first described in the 16th century by the Ital-
ian anatomist Eustachi [40]. However, only in 1855 did 
Addison realize the importance of this organ for survival. 
In  the  first  half  of  the  20th  century,  scientists  finally 
discovered the importance of cortical hormones which, 
in the 1940s, were shown not only to be involved in the 
stress response but also to exert potent anti-inflammatory 
activity [41].
GC synthesis is under the control of the hypothalamus-
pituitary-adrenal  (HPA)  axis,  which  controls  hormone 
levels in the serum [42]. This mechanism involves the 
release of corticotrophin-releasing hormone (CRH) and 
adrenocorticotropic  hormone  (ACTH)  in  response  to 
stress and elevated cytokine levels which results in GC 
secretion from the adrenal gland. GCs ultimately limit 
the activity of the HPA axis at the level of the hypothala-
mus and the pituitary, thus establishing a negative feed-
back loop. Superimposed on that, GC production also 
follows a circadian rhythm, characterized in humans by 
high levels in the morning and low levels in the evening 
[43]. GCs have also been hypothesized to be produced in 
other tissues but the evidence for this remains scarce (see 
below). Collectively, GC action is controlled on multiple 
levels by the neuroendocrine as well as the immune sys-
tem itself.
Animal models investigating GR function in T cells
Loss-of-function mutations
During the last decade, a considerable number of ge-
netically modified mouse strains have been generated to 
study the role of the GR in various physiological settings 
and  anatomical  locations  [15],  including  the  develop-
ment and function of T lymphocytes (table 1). The first 
approach of this kind was described in 1995 when Ash-
well and colleagues expressed an antisense fragment to 
the GR under the control of the proximal lck promoter 
[44]. GR mRNA and protein expression were reduced by 
around half, resulting in a lower thymic cellularity and 
a partial resistance to GC-induced thymocyte apoptosis. 
Intriguingly,  analysis  of  a  second  strain  of  transgenic 
mice which was generated by Okret and collegues us-
ing a largely similar construct arrived at exactly the op-
posite conclusion [45]. In particular, the total thymocyte 
number  in  this  experiment  was  found  to  be  elevated 
instead of diminished.
Analysis of knock-out mice is generally considered more 
reliable than using antisense transgenic animals since de-
letion should be complete and unspecific effects reduced. 
GR knock-out mice were first reported by Schütz and col-
leagues in 1995 [46]. The initial analysis of these mutants 
revealed that they die perinataly due to lung atelectasis. It 
took several years before the thymic phenotype of these 
mice was investigated using fetal mice and bone marrow 
chimeras.  Thymocytes  derived  from  these  knock-out 
mice were found to be completely resistant to GC-in-
duced apoptosis but otherwise no significant differences 
in cell number, subtype distribution and thymic selection 
were observed [47, 48]. Muglia and colleagues described 
another strain of GR-deficient mice, confirming the lack 
of any role for the GR in the thymus beyond inducing 
apoptosis [13]. Recently, two strains of T cell-specific 
GR knock-out mice were generated by independent labo-
ratories. Like GR-deficient mice, these mutants turned 
out to be resistant to GC-induced apoptosis while having 
normal thymic cellularity and subtype distribution [12, 
49]. As mentioned earlier, the GR modulates transcrip-
tion through two principal modes of action. These can 
be dissected using the previously described GRdim mice 
which are impaired in their ability to transactivate genes 
from GRE-containing promoters [8]. While no effect on 
T cell development was detected, thymocytes from these 
knock-in mice were refractory to GC-induced cell death 
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activity of the GR is dispensable for T cell development 
but essential for thymocyte apoptosis. Collectively, the 
analysis of all five GR mutant mouse strains has consist-
ently failed to demonstrate a role for the receptor in T 
cell development and thymic selection which contrasts 
with the observations made in antisense transgenic mice 
(table 1). In conclusion, GCs, at least when acting via the 
classical GR, seem unlikely to be involved in these proc-
esses while their role in inducing thymocyte apoptosis is 
beyond question.
Gain-of-function mutations
Two  mouse  strains  displaying  increased  GR  signaling 
have been described in recent years (table 1). The first 
approach  aimed  at  doubling  the  GR  gene  dosage  by 
introducing a large DNA fragment covering the whole 
genomic locus into the germline of mice [50]. In accord-
ance with the increased GR expression, transgenic thy-
mocytes were more sensitive to GC-induced apoptosis 
than control cells. This indicates that apoptosis critically 
depends on the amount of GR protein in the cell. In the 
second transgenic mouse line, GR overexpression was 
targeted  to  developing  thymocytes  by  expressing  the 
GR under the control of the proximal lck promoter [45]. 
Overexpression was accompanied by increased sensitiv-
ity to GC-induced apoptosis, lower recovery of thymo-
cytes and reduced numbers of peripheral T cells. The 
same group recently reported the generation of another 
mouse strain characterized by conditional GR expression 
in thymocytes and T cells [51]. Upon induction of the 
GR, thymic cellularity was reduced, both in the presence 
and absence of adrenally derived GCs, although no influ-
ence on subtype distribution could be demonstrated (ta-
ble 1). This was interpreted as a proof for GCs of thymic 
origin, a conclusion which is not supported by our own 
studies [unpublished data].
Apoptosis
The concept of apoptosis and its function in the im-
mune system
Apoptosis  is  defined  by  a  series  of  molecular  and 
morphological  events  involving  the  loss  of  mitochon-
drial membrane potential, chromatin condensation, DNA 
fragmentation, membrane blebbing and the generation of 
apoptotic vesicles (fig. 2). Mediated by executioner cas-
pases, this process culminates in the orchestrated disas-
sembly and phagocytosis of the dying cell [52].
Apoptosis  is  essential  for  the  development  and  main-
tenance of the immune system [4]. It may be initiated 
because  the  developing  lymphocytes  fail  to  express  a 
productively rearranged antigen receptor or alternatively 
because they produce a receptor displaying too weak or 
too strong of an affinity for MHC/self-peptide [1]. These 
selection  steps  ensure  proper  recognition  of  a  broad 
range of foreign antigens and help to achieve tolerance 
and prevent autoimmune diseases. Apoptosis is not only 
Table 1. Transgenesis and gene-targeting experiments addressing GR function in T lymphocytes.
Strain  Type of mutation  T cell phenotype  Ref.
GRTKO  T cell-specific GR antisense   reduced thymocyte number, lower sensitivity to GC-induced   44, 123, 
  transgenic mouse  apoptosis, altered T cell development and function  124, 130
lck
Pr-asGR  T cell-specific GR antisense   elevated number of thymocytes, in particular DP and CD4 single-  45
  transgenic mouse  positive cells
GR
hypo   GR knock-out mouse   unaltered thymocyte number and subtype distribution, thymocytes   46, 48
(GRKO)  (hypomorphic allele)  refractory to GC-induced apoptosis, normal T cell function
GRN  GR knock-out mouse   thymic cellularity and subtype distribution unaltered  131
  (exon 3 deleted)
GRKO  GR knock-out mouse   unaltered thymic cellularity and subtype distribution, thymocytes refractory   13
  (exon 2 deleted)  to GC-induced apoptosis, mice resistant to aCD3-induced apoptosis in vivo
TGRKO  T cell-specific GR knock-out   thymocyte number and subtype distribution unaltered, high mortality after   49
  mouse (exon 2 deleted)  aCD3-induced polyclonal T cell activation
GR
lckcre  T cell-specific GR knock-out   no phenotypic characterization published, GCs are unable to counteract   12
  mouse (exon 3 deleted)  AICD
GR
dim  GR knock-in mouse carrying   thymocyte number and subtype distribution unaltered, thymocytes   8, 33, 12
  the point mutation A458T   refractory to GC-induced apoptosis, repression of cytokine expression in 
    thymocytes and splenic T cells normal, GCs unable to counteract AICD
YGR  ubiquitous GR overexpression   increased sensitivity towards GC-induced thymocyte apoptosis  50
  (increased gene dosage) 
lck
Pr-sGR  T cell-specific GR   GC-induced thymocyte apoptosis increased, reduced thymocyte and   45
  overexpression  peripheral T cell number
hCD2-GR  conditional T cell-specific   reduced thymic cellularity after induction of GR overexpression, even in   51
  GR overexpression  adrenalectomized animals64  M. J. Herold, K. G. McPherson and H. M. Reichardt  Glucocorticoid actions in T cells Cell. Mol. Life Sci.    Vol. 63, 2006  Review Article  65
critical to the establishment of the immune system but 
also plays an important role in the termination of adap-
tive immune responses [3]. During the contraction phase, 
clonally  expanded  antigen-specific  lymphocytes  are 
rapidly removed by AICD, a process induced by TCR 
triggering and cytokine withdrawl. This serves to prevent 
uncontrolled proliferation of activated lymphocytes and 
thereby avoids immunopathology and autoimmune dis-
orders.
The pathways of apoptosis
Lymphocytes are known to undergo two distinct apop-
totic pathways which have been well characterized in re-
cent years [4] (fig. 2). One is initiated by cellular stress or 
high-affinity ligation of antigen receptors during negative 
selection of autoreactive lymphocytes. This so-called ‘in-
trinsic’ pathway is regulated by the interplay of pro- and 
anti-apoptotic members of the Bcl-2 family at the level 
of the mitochondria [53]. The second mechanism, also 
known as the ‘extrinsic’ apoptotic pathway, is activated 
by ligation of death receptors and occurs, for example, 
during AICD [3]. These two pathways share common 
downstream components such as certain caspases, a fam-
ily of aspartate-specific proteases. 
Initiation of the ‘intrinsic’ pathway involves the release 
of apoptotic mediators from the mitochondria following 
disruption  of  its  outer  membrane  [54]. This  is  tightly 
regulated by the balance between pro- and anti-apoptotic 
Bcl-2 family members (fig. 2). Pro-apoptotic factors of 
the so-called ‘BH3-only’ family such as Bim, Bid, Bad, 
Puma and Noxa serve as conduits of apoptotic stimuli by 
activating the ‘multi-domain’ family members Bax and 
Bak [55, 56]. This process is opposed by anti-apoptotic 
Bcl-2 family members such as Bcl-2 and Bcl-xL which 
bind and neutralize their pro-apoptotic counterparts [53, 
57–60]. Following formation of pores in the outer mito-
chondrial membrane by Bax and Bak, cytochrome c is 
released, resulting in the formation of the so-called ‘ap-
optosome’ (fig. 2). This multimeric complex containing 
caspase-9 and Apaf1 activates caspase-3 which finally 
leads to apoptosis [52]. 
The ‘extrinsic’ apoptotic pathway is initiated by the liga-
tion, oligomerization and subsequent activation of death 
receptors as typified by Fas [61] and results in the activa-
tion of caspase-8 (fig. 2). Depending on the cell type, sub-
sequent activation of caspase-3 occurs either directly or 
requires an additional amplification loop involving cleav-
age of the pro-apoptotic factor Bid and destabilization 
of the mitochondrial membrane. However, irrespective 
of which biochemical events are involved, the ‘intrinsic’ 
and the ‘extrinsic’ pathway both converge on the activa-
tion of caspase-3, the point of no return in most cell death 
cascades (fig. 2).
Although the two aforementioned pathways are consid-
ered to explain most forms of apoptosis, evidence for 
alternative pathways is accumulating [62, 63]. One pos-
tulated mechanism involves the destabilization of lyso-
somal membranes and subsequent release of cathepsins 
B and D [64] (fig. 2). This results not only in generalized 
proteolysis but also causes disruption of the outer mito-
chondrial membrane and caspase-3 activation [65–68]. 
A second unconventional pathway involves the release 
Figure 2. The major pathways 
of lymphocyte apoptosis. The 
‘intrinsic’  pathway  involves 
the  activation  of  ‘BH3-only’ 
molecules  (Bad,  Bim  etc.) 
which  in  turn  activate  the 
‘multidomain’  proteins  Bax 
and  Bak.  This  leads  to  the 
formation of the ‘apoptosome’ 
and  activation  of  caspase-3, 
a  process  which  is  counter-
acted  by  the  anti-apoptotic 
proteins  Bcl-2  and  Bcl-xL. 
The  ‘extrinsic’  pathway  is 
initiated  by  oligomerization 
of death receptors followed by 
caspase-8 activation and also 
converges  on  caspase-3.  An 
alternative  pathway  induced 
by  lysosomal  stress  involves 
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of death-inducing factors from the mitochondria such as 
AIF and endonuclease G, which are capable of initiating 
cell death independently of caspases [63].
The mechanism of GC-induced apoptosis
Initiation of GC-induced apoptosis. The current model 
implies that GC-induced apoptosis requires the presence 
of a functional GR and in particular its transactivating 
function [8,13, 15, 47, 50]. Although most data suggest 
that initiation of cell death by GCs is linked to de novo 
gene expression, it is noteworthy that some events may 
also involve so-called non-genomic actions of the GR 
(fig. 3).
During the last couple of years several approaches to 
identify  GC-induced  genes  have  been  undertaken,  but 
only a few convincing candidates were identified. Genes 
described to be up- or downregulated during GC-induced 
apoptosis include c-myc [69], tdag8 [70, 71], dig2 [72], 
Bim [73, 74] and PUMA [75]. Furthermore, large-scale 
expression analysis of GC-regulated genes has only been 
reported in cell lines so far. Both Tonko et al. [76] and 
Medh et al. [77] have studied GC-induced gene regula-
tion in leukemic lymphoid CEM cells, whereas Wang et 
al. [73] have performed a large-scale analysis examining 
the two murine lymphoma cell lines S49.A2 and WEHI 
7.2 [73]. The most promising gene identified in these 
screens is the pro-apoptotic protein Bim, but its function 
in  this  process  still  requires  further  investigation  (see 
below).
The role of Bcl-2 proteins in GC-induced apoptosis
A plethora of experiments have implicated pro- and anti-
apoptotic Bcl-2 family members in GC-induced apopto-
sis. Mice reconstituted with fetal liver cells from Bcl-2 
transgenic mice [78, 79] as well as Bcl-2-overexpressing 
murine lymphoma cells [80, 81] are protected from GC-
induced cell death, indicating that the disruption of mito-
chondrial integrity is essential to GC-induced apoptosis 
[82]. Studies carried out in murine T hybridoma cells 
suggest that Bcl-2 overexpression also blocks the release 
of both cytochrome c and AIF in response to GCs [83]. 
The importance of Bcl-2 is further underscored by the 
analysis of Bcl-2-deficient mice which display fulminant 
lymphoid apoptosis in vivo and enhanced cell death of 
thymocytes in vitro after GC treatment [84]. Collectively, 
these data suggest that the level of Bcl-2 determines the 
sensitivity to GCs. Since Bcl-2 is known to localize and 
act in mitochondria as well as the endoplasmatic reticu-
lum, both organelles might play an important role in GC-
induced apoptosis [58]. 
The role of Bcl-xL in this process is less clear. Bcl-xL 
becomes  redistributed  to  the  mitochondria  following 
GC treatment which can be prevented by inhibitors of 
translation  [85,  86].  Overexpression  of  Bcl-xL  in  a  T 
hybridoma  cell  line  can  block  GC-induced  apoptosis 
[80] and sustained Bcl-xL expression was found to be a 
prerequisite for the resistance of single-positive thymo-
cytes to GC-induced apoptosis in vivo [87]. Thus, Bcl-xL 
contributes to determining the sensitivity of lymphocytes 
to GC-induced apoptosis although this might be limited 
to certain developmental stages of T lymphocytes. Since 
Bcl-xL-deficient mice die around embryonic day 13 [88] 
and neither mice reconstituted with fetal liver cells nor 
tissue-specific knock-out mice have been described, fur-
ther analysis of Bcl-xL function in GC-induced apoptosis 
in vivo is not possible at this point.
The pro-apoptotic members of the Bcl-2 family have also 
been implicated in GC-induced apoptosis. The role of the 
‘multidomain’ members Bax and Bak has been assessed 
by gene targeting [89–92]. While thymocytes from in-
dividual knock-out mice showed no difference in their 
sensitivity to GC-induced apoptosis, in the absence of 
both molecules, thymocytes were completely resistant. 
This suggests that Bax and Bak are involved in mediating 
GC effects but at the same time fulfill redundant roles. 
As to how GCs affect Bax and Bak, nothing is known 
so  far.  Bax  is  partially  redistributed  from  the  cytosol 
to the membrane fraction upon GC treatment [85, 86]. 
However, given the redundancy of Bax and Bak, GCs, 
possibly through ‘BH3-only’ proteins such as Bim, are 
more likely to induce a conformational change of these 
pro-apoptotic proteins which then leads to destabilization 
of the mitochondrial membrane.
The  current  model  of  the  pro-apoptotic  ‘BH3-only’ 
proteins  implies  that  individual  family  members  are 
responsible for mediating the response to different ap-
optotic stimuli [53, 93]. Bid, for example, is known for 
its involvement in Fas-mediated apoptosis in certain cells 
[94]. In keeping with this notion, GC-induced thymocyte 
apoptosis was unaffected in Bid-deficient mice, excluding 
Figure 3. Cellular processes involved in GC-induced apoptosis. Bcl-
2 family: transcription of Bim and Puma is upregulated; caspases: 
caspase-3, -8 and -9 are activated. lysosomes: cathepsin B is re-
leased. proteasomal degradation: c-IAP1 and XIAP are degraded at 
the protein level; H2O2 levels are increased; ceramides are produced, 
and Na
+/ K
+ levels altered. The IP3 receptor is engaged. Kinases: 
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an essential role in GC-mediated cell death [95]. The role 
of Bad, which is posttranscriptionally regulated by Akt/
PKB-dependent phosphorylation, has been addressed in 
T cell-specific transgenic mice. Overexpression of Bad 
sensitized  thymocytes  to  GC-induced  apoptosis  [96]. 
However, this may simply reflect its antagonistic effect 
on the death-repressing activity of Bcl-xL and thus Bad is 
not involved in this process under normal circumstances. 
Unfortunately, the role of Bad in GC-induced apoptosis 
has neither been investigated in the recently published 
Bad-deficient mice nor in a strain of knock-in mice in 
which BAD can not be phosphorylated due to three engi-
neered point mutations [97, 98].
As  outlined  above,  Bim  was  identified  in  one  of  the 
large-scale screenings as being upregulated during GC-
induced  apoptosis  in  T  lymphoma  cell  lines  [73].  In 
keeping with this observation, reducing Bim levels by 
RNAi in pre-B ALL cell lines rendered them partially re-
sistant to GC-induced apoptosis [74]. Furthermore, GC-
induced apoptosis in Bim-deficient mice was partially 
impaired compared to wild-type animals [78, 79]. In this 
context, it is interesting that PUMA was also shown to be 
upregulated in response to GC treatment [75]. In addi-
tion, analysis of two distinct strains of PUMA knock-out 
mice by independent laboratories has revealed a partial 
resistance of thymocytes to GC-induced apoptosis [99, 
100]. In contrast, Noxa knock-out mice do not appear to 
be compromised in this process. Taken together, Bim and 
PUMA are the most promising candidates for pro-ap-
optotic ‘BH3-only’ proteins induced by GCs during the 
initiation of apoptosis.
The role of caspases in GC-induced apoptosis
The involvement of caspases in GC-induced apoptosis 
is  continually  debated.  Pharmacological  inhibition  of 
caspases can be achieved by application of chemically 
modified small-peptide derivatives but their specificity 
for  individual  family  members  is  sometimes  variable 
[101]. Taking such an approach, thymocytes were found 
to be refractory to GC treatment in the presence of the 
pan-caspase inhibitor z-VAD-fmk [82, 102]. Moreover, 
caspase-3 and -8 were proposed to mediate GC-induced 
apoptosis but whether this holds true for all cell types 
needs to be demonstrated [103]. In particular, our own 
unpublished results have revealed that the role of cas-
pases in this process is cell type specific. In summary, 
experiments based on the pharmacological interference 
with  caspase  activity  suggest  some  role  for  these  en-
zymes in GC-induced thymocyte apoptosis.
In contrast, analysis of knock-out mice deficient in indi-
vidual caspases led to contradictory conclusions. First, 
thymocytes and mature T cells derived from caspase-1- 
and caspase-2-deficient mice, as well as from mice with 
a  T  lymphocyte-specific  deletion  of  caspase-8,  show 
no differences from wild-type mice in their responsive-
ness to GC treatment [104–106]. In contrast, apoptosis 
in  response  to  GCs  was  found  to  be  reduced  in  both 
caspase-9- and Apaf-1-deficient mice [107, 108]. Since 
these animals suffer from severe developmental defects, 
the impaired apoptosis could also result from unspecific 
effects. This notion is supported by the analysis of ani-
mals reconstituted with fetal liver cells from Apaf-1- or 
caspase-9-deficient mice. Thymocytes and mature T cells 
from these mice undergo apoptosis in response to a large 
range of GC concentrations, suggesting that the intrinsic 
lack of caspase-9 and Apaf-1 in T lymphocytes does not 
impair GC-induced apoptosis [79]. Interestingly, thymo-
cytes from caspase-3-deficient mice, which die within 
the first month after birth, show normal responsiveness 
to GC-induced apoptosis [109]. This is in sharp contrast 
to the pharmacological data which are in support of an 
important role for caspase-3 in this process [103]. How-
ever, other family members conceivably compensate for 
its lack under these circumstances.
Other mediators of GC-induced apoptosis
There is growing evidence that lysosomes may play an 
important role in both caspase-dependent and -independ-
ent forms of apoptosis [67]. We have recently shown that 
activation  of  cathepsin  B  precedes  caspase  activation 
during GC-induced cell death, suggesting an important 
role for this cellular compartment [unpublished data].
Several studies have implicated the proteasome complex 
in GC-induced thymocyte apoptosis [110]. Its pharmaco-
logical inhibition prevents disruption of the mitochondri-
al membrane potential and nuclear fragmentation in thy-
mocytes. Furthermore, the apoptosis inhibitory proteins 
c-IAP1 and XIAP have been shown to be degraded by 
the proteasome following GC treatment [111]. Although 
good evidence exists for an important role for proteaso-
mal degradation, our unpublished results suggest that this 
is limited to certain cell types rather than being part of a 
ubiquitious pathway of GC-induced apoptosis.
Hydrogen peroxide, which can act as a second messenger 
in cell signaling, is synthesized at modest levels follow-
ing the ligation of cell surface receptors and in response 
to  various  apoptotic  stimuli  [112].  Evidence  that  this 
pathway can be initiated by GCs comes from the obser-
vation that treatment of thymocytes with GCs leads to an 
increase in the intracellular level of hydrogen peroxide 
[110]. This precedes the loss in mitochondrial membrane 
potential, cytochrome c release and caspase-3 activation. 
However, in our hands, attempts to repeat this experiment 
failed [unpublished data].
Additional  events  that  have  been  hypothesized  to  be 
involved  in  GC-induced  apoptosis  include  ceramide 
production [113], changes in the intracellular levels of 
sodium  and  potassium  ions  [114],  activation  of  PI3K 
[35] and the inositol trisphosphate receptor [115], as well 
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protein kinase C, Raf and members of the 14-3-3 fam-
ily [116]. Importantly, some of these events have been 
shown to occur in the cytosol independent of de novo 
gene  expression  [35]  but  their  relative  contribution  to 
GR-mediated apoptosis remains elusive. For further in-
formation on the non-classical effects of GCs, the reader 
is directed to a review by Distelhorst [9]. 
The  cell  type  specificity  of  GC-induced  thymocyte 
apoptosis
It was recognized more than 20 years ago that thymocytes 
differ in their sensitivity to GC treatment dependent on 
their developmental stage [117]. When administered at 
pharmacological doses, CD4+CD8+ double-positve (DP) 
thymocytes undergo cell death in vivo whereas single-
positive (SP) thymocytes are resistant to GCs (fig. 4). We 
have recently proposed a model involving CD28-mediat-
ed protection of SP thymocytes to explain this difference 
[87]. Such a specific role for CD28 in mature thymocytes 
is also suggested by the finding that its expression in hu-
mans and rats increases during the course of thymocyte 
development [118] and that its principal ligands B7-1 and 
B7-2 are exclusively expressed by thymic medullary cells 
where the mature T cells reside [119] .
Although refractory to GC-induced cell death in vivo, SP 
thymocytes become sensitive when in culture. However, 
enforced CD28 signaling in the absence of TCR engage-
ment restores their resistance to GC treatment, presum-
ably by upregulating Bcl-xL [87]. This model is consist-
ent with the previous finding that anti-apoptotic proteins 
such as Bcl-2 and Bcl-XL are developmentally regulated 
during thymocyte development [120–122]. Similarly, SP 
thymocytes  in  CD28  knock-out  mice  show  increased 
sensitivity  to  GC-administration.  This  suggests  that 
CD28 signaling is responsible for conferring resistance 
to GCs in vivo. The differential sensitivity of immature 
DP and mature SP thymocytes to apoptosis may form 
the basis for the postulated role GCs play in positive and 
negative selection [11] (see below). If this model holds 
true, DP thymocytes need to be sensitive to GCs during 
selection but loose responsiveness to the same stimulus 
upon maturation. This could be achieved by the translo-
cation of selected SP thymocytes from the cortical region 
to the medulla, where they would come into close contact 
to B7-expressing epithelial cells. Subsequent ligation of 
CD28 on these cortical SP thymocytes would then afford 
them protection from GCs.
Glucocorticoids and T cell development
GCs and thymic selection
An  important  checkpoint  of  T  cell  development  oc-
curs at the DP stage where interaction of the TCR with 
MHC/self-peptides on thymic epithelial and stromal cells 
initiates selection processes that lead to death by neglect, 
positive or negative selection [1]. At this stage, the major-
ity of DP thymocytes die due to their inefficient ability to 
interact with self-ligands in the context of MHC. Accord-
ing to the avidity model of selection, DP cells with TCRs 
that interact with moderate affinity to self-ligands will be 
positively selected and further differentiate into mature 
functional T cells [2]. High-affinity interaction with self-
MHC, which would be equivalent to autoreactivity in the 
periphery, destines DP cells to apoptosis and thus results 
in negative selection. 
Most models of positive and negative selection postulate 
that the strength of TCR signaling determines thymocyte 
fate. In the ’mutual antagonism’ model, this is assigned 
to an interplay between GC- and TCR-induced apoptosis 
[11]. Alone, signaling through the TCR or GR induces 
apoptosis,  but  when  both  receptors  are  coordinately 
stimulated they oppose each other (fig. 4). Thus, thymo-
cytes expressing a TCR with high affinity for MHC/self-
peptide undergo negative selection since GR signaling is 
not sufficient to overcome the strong signal originating 
from the TCR. In contrast, thymocytes with low-avidity 
TCRs undergo GC-induced cell death, since in this case 
the TCR signal cannot override GR signaling. Finally, in 
thymocytes with moderate-avidity TCRs, the two signals 
neutralize each other and thereby rescue the cells from 
apoptosis.
Figure 4. The role of GCs in thymocyte development. At the dou-
ble-positive (DP) stage developing thymocytes undergo positive and 
negative selection which is controlled by an interplay between GR- 
and T cell receptor (TCR)-derived signals. Mature single-positive 
(SP) thymocytes are protected from GC-induced apoptosis by CD28 
signaling. cTEC, cortical thymic epithelial cell; DC, dendritic cells; 
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Since the ‘mutual antagonism’ model was proposed, ar-
guments both in favour and against it have been put for-
ward. Analysis of mice expressing an antisense GR in the 
thymus were found to possess a T cell repertoire which 
is shifted toward cells with lower affinity for MHC/self-
peptide and thus have a reduced number of potentially 
autoreactive cells [44, 123, 124]. In contrast, analysis of 
several strains of GR knock-out mice failed to provide 
any  support  for  the  ‘mutual  antagonism’  model  [13, 
47–49]. However, most of these strains have not been 
analyzed for more subtle effects on the antigen receptor 
repertoire. Thus, the idea that GC-induced apoptosis par-
ticipates in thymic selection remains attractive, although 
it awaits further support by more refined approaches.
The role of thymus-derived GCs
There has been a long-standing debate as to whether the 
thymus synthesizes GCs itself or whether this is an exclu-
sive characteristic of the adrenal gland [125] (fig. 4). The 
presence of the necessary biosynthetic machinery was 
demonstrated  in  the  thymus  [126].  In  agreement  with 
this finding, thymic epithelial cells (TECs) were shown 
to convert GC precursors to deoxycorticosterone in vitro 
[127,  128].  In  addition,  TECs  also  make  metabolites 
which are able to activate GR-dependent transcription 
[127]. In fetal thymus organ culture, inhibition of GC 
synthesis by metyrapone turned out to impact on apop-
tosis, suggesting that steroid hormones might indeed be 
produced in the thymus [126]. However, another group 
could show that metyrapone impairs thymocyte develop-
ment regardless of the presence or absence of a func-
tional GR, indicating that this reagent inhibits thymocyte 
development  in  an  unspecific  fashion  [48].  Recently, 
Okret and colleagues reported a new transgenic mouse 
model in which overexpression of the GR in thymocytes 
was controlled by the tetracycline-inducible system [51]. 
Increased expression of the GR in mice lacking adrenally 
derived GCs caused a slight reduction in thymic cellular-
ity while subtype composition was unaltered. This ob-
servation was assigned to increased apoptosis following 
induction of GR overexpression. The finding that appli-
cation of the GR antagonist RU486 was able to increase 
thymic cellularity even in adrenalectomized mice was 
taken as additional evidence of a role for intrathymically-
synthesized GCs. However, our own unpublished results 
argue  against  extra-adrenal  GC  synthesis.  Thymocyte 
numbers in transgenic rats overexpressing a mutant GR 
with increased ligand affinity are dramatically reduced 
while adrenalectomy restored cellularity within 3 weeks 
after surgery [unpublished data]. Thus, on the basis of 
our own findings, a major role for thymic GCs in T cell 
apoptosis and development is unlikely. However, more 
subtle influences on thymocyte selection, such as those 
suggested by the mutual antagonism model still remain 
possible.
Concluding remarks
Since the cloning of the GR [129] and the observation 
that GCs induce the death of T cells [6], we have come 
a long way in understanding the mechanisms underlying 
the actions of these hormones in T cell apoptosis and 
development. However, we are still far from having a 
coherent picture of either the physiological role or the 
molecular mechanisms of GCs in these processes. For 
example,  we  have  limited  knowledge  of  which  genes 
are essential for T cell apoptosis. The issue of thymus-
derived GCs and the involvement of these hormones in 
thymocyte selection also remains debatable. Transgen-
esis and gene targeting have contributed enormously to 
our current understanding of GC action but new animal 
models carrying more refined mutations and transgenes 
are required to adequately address these questions. This 
is not only essential to extend our theoretical knowledge 
but is also of clinical relevance, since GCs are still among 
the most widely prescribed drugs for the treatment of 
hematological  malignancies  owing  to  their  ability  to 
mediate apoptosis in leukemia, lymphoma and myeloma 
cells [10, 14]. Thus, despite the long history of research 
on GC-induced apoptosis, it will continue to be a fertile 
and fascinating ground for basic and applied biomedical 
studies.
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